Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Corvus Pharma Com (CRVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 109,807
  • Shares Outstanding, K 29,282
  • Annual Sales, $ 0 K
  • Annual Income, $ -55,660 K
  • 36-Month Beta 0.90
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.99

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.40
  • Number of Estimates 2
  • High Estimate -0.39
  • Low Estimate -0.41
  • Prior Year -0.58
  • Growth Rate Est. (year over year) +31.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.22 +11.18%
on 12/26/18
4.83 -25.88%
on 01/08/19
-0.54 (-13.11%)
since 12/21/18
3-Month
3.22 +11.18%
on 12/26/18
8.46 -57.68%
on 11/02/18
-4.57 (-56.07%)
since 10/23/18
52-Week
3.22 +11.18%
on 12/26/18
13.91 -74.26%
on 06/15/18
-6.28 (-63.69%)
since 01/23/18

Most Recent Stories

More News
Corvus Announces Presentation of Preclinical Data on CPI-818, a First-in-class Covalent Inhibitor of ITK Targeting T-Cell Lymphomas

Company on track to submit Investigational New Drug application for CPI-818 in early 2019

CRVS : 3.67 (-2.13%)
Corvus Announces Enrollment in Second Arm of Phase 1/1b Dose-Escalation Trial of Anti-CD73 Antibody, CPI-006, Focused on Combination with CPI-444 Adenosine Antagonist

Both CPI-006 monotherapy and CPI-006 in combination with CPI-444 trial arms now enrolling patients at U.S. sites

CRVS : 3.67 (-2.13%)
Ziopharm Oncology (ZIOP) in Focus: Stock Moves 6.2% Higher

Ziopharm Oncology (ZIOP) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

CRVS : 3.67 (-2.13%)
ZIOP : 1.97 (-7.08%)
Sarepta Stock More Than Doubles This Year So Far: Here's Why

Sarepta's (SRPT) key product, Exondys 51, continues to perform well. Its lead pipeline candidate, golodirsen, is also making good progress. The company is also developing gene therapies.

CRVS : 3.67 (-2.13%)
SRPT : 118.42 (-1.55%)
BMRN : 92.75 (-3.04%)
EXEL : 21.70 (-1.85%)
Report: Exploring Fundamental Drivers Behind Berry Petroleum, Quotient, Virco Manufacturing, Corvus Pharmaceuticals, Marine Products, and Hamilton Beach Brands Holding -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Berry Petroleum Corporation...

CRVS : 3.67 (-2.13%)
MPX : 15.80 (-8.19%)
BRY : 10.35 (+1.07%)
HBB : 27.00 (-2.88%)
VIRC : 4.12 (+1.48%)
QTNT : 7.52 (+1.48%)
Corvus Pharmaceuticals to Present at the 27th Annual Credit Suisse Healthcare Conference

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the...

CRVS : 3.67 (-2.13%)
Corvus Pharmaceuticals to Webcast Investor & Analyst Event on November 10, 2018

Event will provide a review of new CPI-444 and CPI-006 data presented at SITC & ESMO

CRVS : 3.67 (-2.13%)
Corvus: 3Q Earnings Snapshot

BURLINGAME, Calif. (AP) _ Corvus Pharmaceuticals Inc. (CRVS) on Thursday reported a loss of $10.5 million in its third quarter.

CRVS : 3.67 (-2.13%)
Corvus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced financial...

CRVS : 3.67 (-2.13%)
Corvus Pharmaceuticals Announces Publication of Preclinical Results Highlighting Antitumor Activity of CPI-444 in Multiple Tumor Models both as Monotherapy and in Combination Studies

BURLINGAME, Calif., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely...

CRVS : 3.67 (-2.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More Share

Trade CRVS with:

Business Summary

Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible...

See More

Key Turning Points

2nd Resistance Point 4.43
1st Resistance Point 4.09
Last Price 3.67
1st Support Level 3.51
2nd Support Level 3.27

See More

52-Week High 13.91
Fibonacci 61.8% 9.83
Fibonacci 50% 8.56
Fibonacci 38.2% 7.30
Last Price 3.67
52-Week Low 3.22

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar